Clobazam API Manufacturers
compare suppliers & get competitive offers
To view suppliers for this material, you need to be logged in first.
This is because of international laws regarding narcotic materials. Furthermore, the contents of this page are only accessible if you are professionaly active in the pharmaceutical industry. In case you are, it is possible to register on our platform, and after your account is approved by our team you will be able to view suppliers and send your request.
Looking for Clobazam API 22316-47-8?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Clobazam. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Clobazam
- Synonyms:
- Clobazam , Clobazamum
- Cas Number:
- 22316-47-8
- DrugBank number:
- DB00349
- Unique Ingredient Identifier:
- 2MRO291B4U
About Clobazam
Do you want to know more about Clobazam? You can find a small explanation about it here. Clobazam belongs to the 1-benzodiazepine class of drugs and is expected to have a better side-effect profile compared to older 1-benzodiazepines. It has been marketed as an anxiolytic since 1975 and an anticonvulsant since 1984. The oral preparation was FDA approved on October 21, 2011. An oral suspension is expected to be available in 2013.
You can ask the supplier for more technical information about the product.
Clobazam is a type of Anxiolytics
Anxiolytics, belonging to the pharmaceutical API (Active Pharmaceutical Ingredient) category, are substances utilized in the development of drugs aimed at treating anxiety disorders. Anxiety disorders are prevalent mental health conditions characterized by excessive worry, fear, and unease. Anxiolytics work by modulating certain neurotransmitters in the brain, such as gamma-aminobutyric acid (GABA), which plays a crucial role in reducing neuronal excitability and inducing a calming effect.
These pharmaceutical APIs have revolutionized the management of anxiety disorders, providing relief to millions of individuals worldwide. Anxiolytics can be further classified into various subcategories based on their mechanism of action, including benzodiazepines, selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and others.
Benzodiazepines, the most commonly prescribed anxiolytics, enhance the activity of GABA receptors, thereby producing sedative and hypnotic effects. SSRIs and SNRIs, on the other hand, primarily work by increasing the availability of serotonin and norepinephrine, respectively, in the brain, leading to a positive impact on mood and anxiety.
The development and production of anxiolytics involve stringent quality control measures to ensure their safety and efficacy. Pharmaceutical companies adhere to Good Manufacturing Practices (GMP) guidelines and conduct thorough preclinical and clinical trials to evaluate the compound's pharmacokinetics, efficacy, and adverse effects.
In conclusion, anxiolytics are a crucial category of pharmaceutical APIs used to address anxiety disorders. Through their modulation of neurotransmitters and receptors in the brain, these medications effectively alleviate symptoms and improve the quality of life for individuals affected by anxiety.
